Dharmacon Pockets $5.7M in Series A Financing Round

Aug 26, 2002

NEW YORK, Aug. 26 - Synthetic RNA developer Dharmacon Research has secured $5.7 million in a Series A round of private-equity financing.

Boulder Ventures led the round, which included investments by Telegraph Hill Partners.

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.